MBIO News and Press, Mustang Bio Inc. From 09/03/19

BOTHELL, Wash. , Sept. 3, 2019 /PRNewswire/ --   BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced that Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage b...

NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

Mustang Bio ( MBIO +2.8% ) inks an agreement with CSL Behring for the rights to its Cytegrity stable producer cell line developed and used by St. Jude Children's Research Hospital. It will use it to produce the viral vector for gene therapy MB-107 for the treatment of X-linked severe com...

Mustang Bio ( MBIO ) has been on my speculative watch list for over a year but has never made it to the top or enticed me to press the buy button. The main attraction is the company's technology, which includes gene therapy and CAR-T therapy. Both of these therapies are cutting-edge and have l...

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumor...

Thinly traded micro cap Mustang Bio (NASDAQ: MBIO ) is up  12%  premarket on light volume in response to its announcement that the FDA has designated MB-107, its lentiviral gene therapy, a Regenerative Medicine Advanced Therapy (RMAT) for the treatment of a rare inherited disorde...

RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine   Designation to facilitate expedited development and review of MB-107 for XSCID NEW YORK and MEMPHIS, Tenn., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (NASDAQ: M...

Gainers:  Mmtec (NASDAQ: MTC ) +346% . Deciphera Pharmaceuticals (NASDAQ: DCPH ) +87% . PEDEVCO (NYSEMKT: PED ) +40% . Mustang Bio (NASDAQ: MBIO ) +24% . OptiNose (NASDAQ: OPTN ) +22% . LSC Communications (NYSE: LKSD ) +21% . Foamix Pharmaceuticals (NASDAQ: FOMX ) +18% . Jumia ...

Aurora Cannabis (NYSE: ACB ) initiated with Neutral rating and $7 (6% upside) price target at Piper Jaffray. More news on: Aurora Cannabis Inc., CV Sciences, Inc., Coherus BioSciences, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Thinly traded micro cap Mustang Bio (NASDAQ: MBIO ) announces that the California Institute for Regenerative Medicine has awarded a $9.28M grant to City of Hope to fund an ongoing Phase 1 study of HER2-specific CAR T candidate MB-103 in patients with HER2-positive breast cancer with brain ...